1. Sanderson, R. D., Ramani, V. P. C., Noseda, A., & Barbieri, P. (2018). Roneparstat combined therapy of multiple myeloma. U.S. Patent Application No. 15/556,183 and Casu, Benito, Torri, G., Naggi, A. M., Giannini, G., Pisano, C., & Penco, S."Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect." U.S. Patent No. 7,781,416. 24 Aug. 2010.
2. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting;Naggi;J. Biol. Chem.,2005
3. SST0001, a chemically modified heparin: inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis;Ritchie;Clin. Cancer Res.,2011
4. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases;Cassinelli;Oncotarget,2016
5. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases;Rivara;Future Med. Chem.,2016